Overview
Helps drug and medical device builders understand regulatory requirements clearly.
Funding
Amounts as reported; USD estimates shown only when they matchNo funding records are listed yet.
No funding rows to list.
Valuation
Amounts as reported; USD estimates shown only when they matchNo valuation records are listed yet.
No valuation rows to list.
Revenue
Amounts as reported; USD estimates shown only when they matchListed 1 revenue record.
No chartable revenue estimates yet.
1 listed record lack a clear date or positive USD estimate for the chart.
| Revenue date | Amount | Sources |
|---|---|---|
| Aug 5, 2026 | 收入增长5倍（上线半年） | 1 source Source ↗ |
Evidence Rhizome AI grows revenue 5 times within six months of launchOn 2026/8/5, LinkedIn reported that Rhizome AI, a US life sciences regulatory intelligence company, doubled the number of countries it covered, grew users to 3 times their previous level, and increased revenue 5 times within six months of launch. It provides traceable regulatory intelligence services to enterprises. Translated source brief, not a quotation. Check the original before citing. Sources · 1
| ||
Select ▸ on a row to see its source brief and links.
Team, products & investors
Explore
More Industry apps companies
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
帮助药械企业理解监管要求的AI平台 Helps drug and medical device builders understand regulatory requirements clearly.